4Matsuo K, Ahn EH, Prather CP, Eno ML, Im DD, Rosenshein NB. Patient-reported symptoms and survival in ovarian cancer. Int J Gynecol Cancer, 2011, 21 (9) : 1555-1565.
5Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Com- parison of four malignancy risk indices in the preoperative evalua- tion of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol, 2009, 144 (2): 163-167.
6Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dre- scher CW, Paley P, Urban N. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol, 2010, ii6 (3) : 378-383.
7Muteh DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol, 2014, 133 (3) : 401- 404.
8Meray O, Tiirkqtio~lu I, Meydanh MM, Kafkash A. Risk of ma- lignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor. J Turk Ger Gynecol Assoc, 2010, 11 (1): 22-26.
9Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treat- ment, and follow-up of borderline ovarian tumors. Oncologist, 2012, 17 (12): 1515-1533.
10Akhtar-Danesh N, Elit L, Lytwyn A. Temporal trends in the rela- tive survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study. Gyneeol Oneol, 2011, 123 (2): 192-195.
